GlassScriptPhysician profile
Lauren Knoten
NPI 1194268524
$2,757.25
in general payments reported to CMS, 2019-2025
24 companies · $1,912 in 2025
The $1,912 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.07 · 2023: $344 · 2024: $463 · 2025: $1,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,442 · Education: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,442.20 |
| Education | $276.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,233.52 | 2023-2025 | |
| Janssen Biotech, INC. | $383.77 | 2025 | Rybrevant, Carvykti, Erleada |
| Puma Biotechnology, INC. | $163.73 | 2025 | |
| Novartis Pharmaceuticals Corporation | $112.03 | 2025 | |
| Revance Therapeutics, INC. | $103.14 | 2025 | Daxxify |
| Merck Sharp & Dohme LLC | $101.99 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Seagen INC. | $99.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $92.42 | 2025 | Libtayo |
| Glaxosmithkline, LLC. | $77.11 | 2025 | Ojjaara, Blenrep |
| Daiichi Sankyo INC. | $52.21 | 2025 | Datroway, Enhertu |
| Gilead Sciences, INC. | $44.85 | 2025 | Trodelvy |
| Incyte Corporation | $44.48 | 2025 | Jakafi, Zynyz, Monjuvi |
| Eisai INC. | $36.59 | 2025 | |
| Galderma Laboratories, L.P. | $31.92 | 2025 | |
| Genentech USA, INC. | $24.83 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $22.60 | 2025 | |
| Pfizer INC. | $18.85 | 2025 | |
| Lilly USA, LLC | $18.30 | 2025 | Jaypirca, Verzenio |
| Astrazeneca Pharmaceuticals LP | $18.23 | 2025 | Imfinzi |
| Genzyme Corporation | $17.59 | 2025 | |
| Astellas Pharma US INC | $17.34 | 2025 | Padcev |
| Pharmaessentia USA Corporation | $15.59 | 2025 | Besremi |
| Array Biopharma INC | $13.92 | 2025 | Mektovi, Tukysa, Braftovi |
| Pacira Pharmaceuticals Incorporated | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Knoten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.